Adaptimmune Therapeutics 향후 성장
Future 기준 점검 0/6
현재 Adaptimmune Therapeutics 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.
핵심 정보
n/a
이익 성장률
n/a
EPS 성장률
| Biotechs 이익 성장 | 25.4% |
| 매출 성장률 | n/a |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | None |
| 마지막 업데이트 | n/a |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Feb 11
ADAP.Y: Executive Transition And Deregistration Will Support Future Upside Potential
Analysts have adjusted their price target on Adaptimmune Therapeutics to $1.50, keeping it aligned with their fair value estimate as they factor in an updated discount rate of 13.43%, steady high revenue growth assumptions near 46.25%, a slightly lower projected profit margin close to 16.05%, and a marginally higher future P/E expectation near 19.36. What's in the News Adaptimmune Therapeutics plans executive changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of Adrian Rawcliffe in connection with a company restructuring (Key Developments).내러티브 업데이트 • Jan 26
ADAP.Y: Leadership Restructuring And Deregistration Will Set Up Future Upside Potential
Analysts have trimmed their price target on Adaptimmune Therapeutics to US$1.50 from US$1.50, reflecting updated assumptions around profit margin and future P/E, while keeping their fair value view unchanged. What's in the News Adaptimmune Therapeutics plans leadership changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of former CEO Adrian Rawcliffe in connection with a company restructuring (Key Developments).내러티브 업데이트 • Jan 12
ADAP.Y: Leadership Transition And Deregistration Will Shape Future Upside Potential
Narrative Update on Adaptimmune Therapeutics Analysts have kept their price target for Adaptimmune Therapeutics broadly steady at around $1.50 per share. This reflects updated assumptions for discount rate, revenue growth, profit margin and future P/E that remain closely aligned with prior estimates.내러티브 업데이트 • Dec 16
ADAP.Y: Leadership And Listing Changes Will Drive Future Upside Potential
Narrative Update on Adaptimmune Therapeutics Analysts have modestly increased their price target on Adaptimmune Therapeutics by approximately 3 percent to about 1.50 dollars per share, citing slightly stronger expected revenue growth and a marginally lower future price to earnings multiple in their updated models. What's in the News Chief Financial Officer Chris Hill has been appointed Chief Executive Officer and Director, succeeding long serving executive Adrian Rawcliffe as part of a broader company restructuring, while temporarily retaining his CFO role (company announcement).내러티브 업데이트 • Dec 02
ADAP.Y: Leadership Transition And Deregistration Will Drive Further Upside Potential
Analysts have maintained their price target for Adaptimmune Therapeutics at $1.50. Modest improvements in profitability and valuation ratios are balanced by steady expectations for growth and risk.내러티브 업데이트 • Nov 18
ADAP.Y: Voluntary SEC Deregistration and Index Removals Will Unlock Future Value
Analysts have raised their price target for Adaptimmune Therapeutics from $0.98 to $1.50. This change reflects updated expectations for valuation and revised future earnings metrics.내러티브 업데이트 • Nov 03
ADAP.Y: Compliance Efforts Will Overcome Index Removal To Drive Recovery
Analysts have raised the price target for Adaptimmune Therapeutics from $0.64 to $0.98 per share. This change reflects increased optimism on future revenue growth and profit margins, despite a slightly higher discount rate.내러티브 업데이트 • Aug 22
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Analysts have lowered their price target for Adaptimmune Therapeutics, citing solvency concerns, ongoing strategic uncertainty, and a lack of near-term catalysts, resulting in a revised fair value from $0.714 to $0.638. Analyst Commentary Bearish analysts cite significant solvency and sustainability concerns, questioning whether the company has sufficient financial resources to navigate near-term challenges.내러티브 업데이트 • Aug 07
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Despite a modestly improved revenue growth outlook and a significantly lower forward P/E, consensus analyst sentiment has worsened, leading to a marked price target reduction from $0.96 to $0.714. What's in the News Adaptimmune Therapeutics reached a settlement with MD Anderson Cancer Center to resolve litigation related to a previous strategic alliance, with all claims to be dismissed upon payment.
새로운 내러티브 • Apr 04
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Rapid treatment network expansion and successful TECELRA launch are driving significant future revenue growth and patient access.분석 기사 • Mar 11
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders that were waiting for something to happen have been dealt a...분석 기사 • Jan 01
Investors Don't See Light At End Of Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Tunnel And Push Stock Down 26%
To the annoyance of some shareholders, Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares are down a considerable 26...분석 기사 • Dec 15
Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Nov 15
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Unfortunately for some shareholders, the Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) share price has dived 32% in the...분석 기사 • Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders won't be pleased to see that the share price has had a very...Seeking Alpha • Sep 12
Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Summary Adaptimmune received FDA approval for Tecelra, with a 39% response rate in synovial sarcoma and a boxed warning for cytokine release syndrome. The U.S. population eligible for Tecelra is small, approximately 100-400 patients, based on various eligibility factors. The collaboration with Galapagos provides $70 million upfront and potential milestone payments up to $465 million, expanding the development of uza-cel in solid tumors. Adaptimmune’s Q2 2024 revenue jumped due to deferred revenue from the terminated Genentech collaboration, resulting in a $69.5 million net profit. Given the limited market and logistical complexities, the likelihood of peak revenue exceeding $200 million is low, presenting high investment risk. Read the full article on Seeking AlphaSeeking Alpha • Jul 03
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Summary Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ADAP has a cash runway of around 3 quarters, with potential resources from collaborations and agreements extending it further. Read the full article on Seeking AlphaSeeking Alpha • Apr 26
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Summary Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Therapeutics has a reasonable financial position with $144 million in cash, but the termination of a collaboration deal with Genentech poses a risk. Expenses will be an issue soon. Read the full article on Seeking Alpha분석 기사 • Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares have retraced a considerable 29% in the last month, reversing a...분석 기사 • Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares have continued their recent momentum with a 107% gain in the last...Seeking Alpha • Feb 02
Adaptimmune: Drug Approval Now Imminent?
Summary Adaptimmune's BLA for their T-cell therapy in soft tissue sarcomas has been accepted for review by the FDA. The company's lead candidate, Afami-cel, has shown promising results in synovial sarcoma, with a PDUFA date set for August 4, 2024. Adaptimmune's cash position is low, but expected milestone payments from their collaboration with Genentech may extend their cash runway. Read the full article on Seeking Alpha분석 기사 • Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders are no doubt pleased to see that the share price has bounced...분석 기사 • Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders will have a reason to smile today, with the analysts making...분석 기사 • Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Shareholders in Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) may be thrilled to learn that the analysts have just...분석 기사 • Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Sep 20
Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Summary Adaptimmune Therapeutics plans to file a BLA this year. Despite that, the stock remains depressed. Their cash position is difficult as well.분석 기사 • Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, although...이 섹션에서는 일반적으로 전문 애널리스트들의 컨센서스 추정치를 기반으로 매출 및 이익 성장 전망을 제시하여 투자자들이 회사의 수익 창출 능력을 이해하도록 돕습니다. 그러나 Adaptimmune Therapeutics는 과거 데이터가 충분하지 않고 애널리스트 예측도 없어, 과거 데이터를 단순히 외삽하거나 애널리스트 전망을 사용하여 향후 이익을 신뢰할 수 있게 계산할 수 없습니다.
Simply Wall St가 다루는 기업 중 97%는 과거 재무 데이터를 보유하고 있기 때문에, 이는 상당히 드문 상황입니다.
이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 6/30/2025 | 65 | -170 | -193 | -190 | N/A |
| 3/31/2025 | 180 | -70 | -111 | -108 | N/A |
| 12/31/2024 | 178 | -71 | -76 | -73 | N/A |
| 9/30/2024 | 175 | -45 | -56 | -54 | N/A |
| 6/30/2024 | 141 | -72 | -47 | -44 | N/A |
| 3/31/2024 | 18 | -163 | -138 | -136 | N/A |
| 12/31/2023 | 60 | -114 | -146 | -141 | N/A |
| 9/30/2023 | 71 | -95 | -132 | -124 | N/A |
| 6/30/2023 | 71 | -91 | -145 | -127 | N/A |
| 3/31/2023 | 71 | -114 | -150 | -125 | N/A |
| 12/31/2022 | 27 | -165 | -172 | -142 | N/A |
| 9/30/2022 | 18 | -175 | -40 | -10 | N/A |
| 6/30/2022 | 12 | -176 | -29 | -7 | N/A |
| 3/31/2022 | 9 | -171 | -12 | 3 | N/A |
| 12/31/2021 | 6 | -158 | 2 | 11 | N/A |
| 9/30/2021 | 6 | -156 | -158 | -152 | N/A |
| 6/30/2021 | 6 | -149 | -129 | -124 | N/A |
| 3/31/2021 | 4 | -140 | -121 | -117 | N/A |
| 12/31/2020 | 4 | -130 | -56 | -54 | N/A |
| 9/30/2020 | 3 | -123 | -39 | -37 | N/A |
| 6/30/2020 | 2 | -127 | -52 | -50 | N/A |
| 3/31/2020 | 2 | -138 | -62 | -59 | N/A |
| 12/31/2019 | 1 | -137 | -116 | -113 | N/A |
| 9/30/2019 | 2 | -144 | -134 | -132 | N/A |
| 6/30/2019 | 42 | -99 | -96 | -92 | N/A |
| 3/31/2019 | 51 | -102 | N/A | -93 | N/A |
| 12/31/2018 | 60 | -96 | N/A | -104 | N/A |
| 9/30/2018 | 62 | -87 | N/A | -94 | N/A |
| 6/30/2018 | 49 | -93 | N/A | -91 | N/A |
| 3/31/2018 | 43 | -69 | N/A | -73 | N/A |
| 12/31/2017 | 38 | -70 | N/A | -54 | N/A |
| 9/30/2017 | 42 | -58 | N/A | -31 | N/A |
| 6/30/2017 | 17 | -76 | N/A | -59 | N/A |
| 3/31/2017 | 14 | -78 | N/A | -58 | N/A |
| 12/31/2016 | 14 | -72 | N/A | -48 | N/A |
| 9/30/2016 | 10 | -73 | N/A | -68 | N/A |
| 6/30/2016 | 12 | -61 | N/A | -53 | N/A |
| 3/31/2016 | 15 | -55 | N/A | -45 | N/A |
| 12/31/2015 | 14 | -48 | N/A | -32 | N/A |
| 9/30/2015 | 13 | -19 | N/A | -20 | N/A |
| 6/30/2015 | 10 | -37 | N/A | -30 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: ADAP.Y 의 예상 수익 증가율이 절약률(3.5%)보다 높은지 판단하기에는 데이터가 부족합니다.
수익 vs 시장: ADAP.Y 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.
고성장 수익: ADAP.Y 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.
수익 대 시장: ADAP.Y 의 수익이 US 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.
고성장 매출: ADAP.Y 의 수익이 연간 20%보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: ADAP.Y의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 13:20 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2025/06/30 |
| 연간 수익 | 2024/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Adaptimmune Therapeutics plc는 8명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ying Huang | BofA Global Research |
| Mohit Bansal | Citigroup Inc |
| Reni Benjamin | Raymond James & Associates |